Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

S
Sandeep Batra, MD

Primary Investigator

Enrolling By Invitation
1-50 years
All
Phase 3
250 participants needed
3 Locations

Brief description of study

What is the purpose of this study?
This phase III trial compares the effect of open thoracic surgery (thoracotomy) tohoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgeryype of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chesturgery where the doctor makes several small incisions and uses a small camera to help withving the cancer. This trial is being done evaluate the two different surgery methods forwith osteosarcoma that has spread to the lung to find out which is better.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.

Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed description of study

What will happen during the study?
  • Patients are randomized into 1 of 2 arms.
  • ARM A: Patients undergo open thoracic surgery (thoracotomy).
  • ARM B: Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS).
  • All patients undergo computed tomography (CT) throughout the trial. Patients may also undergoue on study and blood throughout the trial.
  • After completion of study treatment, patients are followed up at 7-14 days, 4-6 weeks, and 3hs post-surgery and then every 3 months for up to 2 years.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Riley, Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma, Riley
  • Age: Between 1 Year - 50 Years
  • Gender: All

Inclusion Criteria:
  • Patients must be < 50 years at the time of enrollment.
  • Patients must have =< 4 nodules per lung consistent with or suspicious for metastases,with at least one of which being >= 3 mm and all of which must be =< 3 cm size.
    • Note: Patient must have eligibility confirmed by rapid central imaging review.
  • Lung nodules must be considered resectable by either open thoracotomy or thoracoscopic
    surgery. Determination of resectability is made by the institutional surgeon.
  • Patients must have a histological diagnosis of osteosarcoma.
  • Patients must have evidence of metastatic lung disease at the time of initialdiagnosis, or at time of 1st recurrence following completion of therapy for initiallyzed disease.
  • Patients with newly diagnosed disease must have completed successful gross tumorheir primary tumor or surgical local control of primary tumor must bed to be performed simultaneously with thoracic surgery.
  • Newly diagnosed patients must be receiving systemic therapy considered by the treatinghysician as at least equivalent to methotrexate, doxorubicin and cisplatin (MAP) athe time of enrollment on this study.
  • Patients at time of 1st recurrence must have previously completed initial systemicherapy for their primary tumor, considered by the treating physician as at leastquivalent to MAP.
Exclusion Criteria:
  • Patients with unresectable primary tumor.
  • Patients with pulmonary metastatic lesions that would require anatomic resection(lobectomy or pneumonectomy) or lesions that are defined as "central" (i.e., centralvolves or is proximal to segmental bronchi and peripheral is lesion distal togmental bronchi).
  • Patients with pleural or mediastinal based metastatic lesions, or with pleuralusion.
  • Patients with disease progression at either the primary or pulmonary metastatic sitewhile on initial therapy. Note: Once the patient has been enrolled on the study,dditional computed tomography (CT) scans are not anticipated prior to thoracicurgery. Note: Some variation in nodule size measurements over the course ofve therapy is anticipated and does not qualify for exclusion unless deemedue disease progression by the primary treatment team.
  • Patients with evidence of extrapulmonary metastatic disease.
  • Patients who received therapeutic pulmonary surgery for lung metastasis prior to.
  • All patients and/or their parents or legal guardians must sign a written informed.
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute(NCI) requirements for human studies must be met.

Updated on 12 Sep 2024. Study ID: AOST2031, PHO-COG-AOST2031, 15628
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center